Copyright
©The Author(s) 2022.
World J Gastroenterol. Jan 14, 2022; 28(2): 216-229
Published online Jan 14, 2022. doi: 10.3748/wjg.v28.i2.216
Published online Jan 14, 2022. doi: 10.3748/wjg.v28.i2.216
Hepatic | Non-hepatic |
Neoplastic | Neoplastic |
Hepatocellular carcinoma | Germ cell tumors (testicular and ovarian malignancies) |
Intrahepatic cholangiocarcinoma | Gastric cancer |
Non-neoplastic | Non-neoplastic |
Liver cirrhosis | Normal pregnancy/infancy |
Fulminant acute hepatitis | Colitis |
Acute and chronic viral hepatitis | Fetal disorders (Gastroschisis, Neural tube defect) |
Chronic liver diseases | Ataxia telangiectasia |
Biliary obstruction (Intrahepatic and extrahepatic causes) | Hereditary tyrosinemia type 1 |
Drug induced hepatitis | Hereditary AFP persistence |
Alcohol liver disease | Beckwith-Wiedemann syndrome |
Non-alcoholic liver disease | Systemic lupus erythematosus |
Neonatal hepatitis | Hirschsprung’s disease |
Massive hepatic necrosis | |
Wilson disease | |
Hemochromatosis |
AFP cut-off value | Sensitivity | Specificity |
20 | Approximately 60% | 90% |
50 | 47% | 96% |
100 | 31.2% | 98.8% |
400 | 17% | 99.4% |
Diagnostic parameter (cut off) | Remark | AUROC |
AFP (> 20 ng/mL) | Sensitivity: 40%–65% | 0.54–0.80 |
Specificity: 76%–96% | ||
AFP-L3 (> 15%) | Sensitivity: 45%–90% | 0.74–0.84 |
Specificity: 95% | ||
AFP-L3 + AFP-P4 + P5 (> 15% for both biomarkers) | Sensitivity: 55.3%–61% | 0.76 |
Specificity: 82.3%–93.9% | ||
AFP, AFP-L3 and DCP (3-25 ng/mL, 1%-10%, 0.48 ng/mL or 40 mAu/mL) | Sensitivity: 81%–93% | 0.88–0.93 |
Specificity: 69%-87% | ||
AFP and GP73 | Sensitivity: 75%-91% | 0.91–0.95 |
Specificity: 81%-97% |
- Citation: Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DTY. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol 2022; 28(2): 216-229
- URL: https://www.wjgnet.com/1007-9327/full/v28/i2/216.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i2.216